Regulatory

Regulatory  ·  Weekly Digest 15 March to 21 March 2025
JSKN003 was granted Breakthrough Therapy Designation in China

Weekly Digest – March 2025 Weekly Digest – March 2025 18 Mar 2025: JSKN003 was granted Breakthrough Therapy Designation in China JSKN003, a HER2-targeting ADC, has been granted BTD by China’s National Medical Products Administration (NMPA) for the treatment of […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 15 March to 21 March 2025
DATROWAY launched in Japan as the first TROP2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer

Weekly Digest – March 2025 Weekly Digest – March 2025 19 Mar 2025: DATROWAY launched in Japan as the first TROP2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer DATROWAY (datopotamab deruxtecan) […]

by Sandhya Ramalingam

Continue Reading